Inclusion Criteria:

          -  Age ≥18 years at the time of informed consent

          -  Histological or cytological diagnosis of ALK-positive advanced NSCLC, CRC with BRAF
             V600E mutation, or RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumor.
             Participants with ROS-positive NSCLC are also eligible for Part 1 and 2

          -  Documentation evidence of biomarker mutation status

          -  Part 3:

        ALK-positive NSCLC with prior lorlatinib and no prior platinum-based chemotherapy (Cohort
        1); with prior lorlatinib and prior platinum-based chemotherapy (Cohort 2); or with no
        prior lorlatinib (Cohort 3).

        BRAF V600E mutant CRC participants resistant to BRAFi plus EGFRi (Cohort 4 ); refractory to
        BRAFi plus EGFRi (Cohort 5); or BRAFi plus EGFRi naïve (Cohort 6).

        RAS- mutant, NF1-mutant or BRAF class 3 mutant solid tumors who have received prior SOC
        (Cohort 7).

        Exclusion Criteria:

          -  Brain metastasis larger than 4 cm

          -  Active malignancy within 3 years

          -  Systemic anti-cancer therapy or small molecule therapeutics within 2 weeks prior to
             start of study treatment. Antibody based agents within 4 weeks prior to start of study
             treatment. Mitomycin C or nitrosoureas within 6 weeks prior to start of study
             treatment.

          -  For participants who may get lorlatinib or encorafenib on study, history of
             interstitial lung disease

          -  For participants who may get binimetinib on study, history or current evidence of
             retinal vein occlusion (RVO) or concurrent neuromuscular disorder associated with
             elevated creatine kinase (CK)